Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,061 to 1,080 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Novel insights into mutual regulation between N6-methyladenosine modification and LncRNAs in tumors. | Cancer Cell Int | 2023 | 37365581 | PubTator, text mining | PubMed |
| Comprehensive analysis of differences in N6-methyladenosine RNA methylomes in Helicobacter pylori infection. | Front Cell Dev Biol | 2023 | 37363723 | PubTator, text mining | PubMed |
| A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth. | Cell Rep | 2023 | 37355987 | PubTator, text mining | PubMed |
| Targeting choroidal vasculopathy via up-regulation of tRNA-derived fragment tRF-22 expression for controlling progression of myopia. | J Transl Med | 2023 | 37355654 | PubTator, text mining | PubMed |
| METTL3-mediated m6A modification of SIRT1 mRNA inhibits progression of endometriosis by cellular senescence enhancing. | J Transl Med | 2023 | 37353804 | PubTator, text mining | PubMed |
Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multicenter cohort study based on super-enhancer profiling. | Theranostics | 2023 | 37351165 | PubTator, text mining | PubMed |
| Roles and implications of mRNA N6 -methyladenosine in cancer. | Cancer Commun (Lond) | 2023 | 37350762 | PubTator, text mining | PubMed |
| Small RNA modifications: regulatory molecules and potential applications. | J Hematol Oncol | 2023 | 37349851 | PubTator, text mining | PubMed |
| Correction: Novel insights into the METTL3-METTL14 complex in musculoskeletal diseases. | Cell Death Discov | 2023 | 37349284 | PubTator, text mining | PubMed |
| The Epigenetic Reader Methyl-CpG-Binding Protein 2 (MeCP2) Is an Emerging Oncogene in Cancer Biology. | Cancers (Basel) | 2023 | 37345019 | PubTator, text mining | PubMed |
| METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma. | BMC Gastroenterol | 2023 | 37344779 | PubTator, text mining | PubMed |
| Qinzhu Liangxue inhibits IL-6-induced hyperproliferation and inflammation in HaCaT cells by regulating METTL14/SOCS3/STAT3 axis. | J Ethnopharmacol | 2023 | 37336334 | PubTator, text mining | PubMed |
| Diagnostic and therapeutic potential of circular RNA in brain tumors. | Neurooncol Adv | 2023 | 37334165 | PubTator, text mining | PubMed |
| Chaperonin CCT controls extracellular vesicle production and cell metabolism through kinesin dynamics. | J Extracell Vesicles | 2023 | 37328936 | PubTator, text mining | PubMed |
| Microenvironment modulation by key regulators of RNA N6-methyladenosine modification in respiratory allergic diseases. | BMC Pulm Med | 2023 | 37328853 | PubTator, text mining | PubMed |
| High FAAP24 expression reveals poor prognosis and an immunosuppressive microenvironment shaping in AML. | Cancer Cell Int | 2023 | 37328842 | PubTator, text mining | PubMed |
| METTL14-Mediated m6A Modification of TNFAIP3 Involved in Inflammation in Patients With Active Rheumatoid Arthritis. | Arthritis Rheumatol | 2023 | 37327357 | PubTator, text mining | PubMed |
| A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts. | Front Immunol | 2023 | 37325647 | PubTator, text mining | PubMed |
| Vital roles of m5C RNA modification in cancer and immune cell biology. | Front Immunol | 2023 | 37325635 | PubTator, text mining | PubMed |
| m6A reader proteins: the executive factors in modulating viral replication and host immune response. | Front Cell Infect Microbiol | 2023 | 37325513 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=54